

U.S.S.N. 10/565,954
Page No. 7

REMARKS

With entry of the present amendment, claims 11 – 29 and 33 – 39 are pending. Claims 1 – 10 and 30 – 32 have been withdrawn as directed to non-elected inventions. Claims 33 – 39 are new. Applicants assert new matter has not been introduced by the new claims. Further, Applicants reserve the right to file continuation and/or divisional applications on the subject matter of any cancelled or withdrawn claim.

New claims 33 – 34 depend from claim 12 and new claims 35 – 39 depend from claim 27. The new claims further define the modified xylanase and support is found in the original claims and at page 17 of the disclosure.

In the instant application, original claims have been subject to a restriction requirement and have been grouped into three inventions:

Group I, claims 1 – 10 drawn to an isolated polynucleotide encoding a polypeptide modified xylanase;

Group II, claims 11 – 23, 24 – 26 and 27 – 29, drawn to an isolated modified polypeptide xylanase or modified enzymes; and

Group III, claims 24 – 26 and 30 – 32, drawn to an isolated polypeptide family 12 cellulase.

Applicants have elected the claims denominated by Group II (claims 11 – 29). Applicants respectfully bring to the Examiner's attention that claims 24 – 26 were categorized in both Group II and Group III. Applicants have included claims 24 – 26 as presently pending claims and have not withdrawn the claims.


In addition to the restriction, the Examiner has required an election of species. Applicants have elected with traverse the following species (AF), a substitution at a position equivalent to position 144 of SEQ ID NO:1. The following claims read on the elected species: independent claims 11, 21, 24 and 27, and dependent claims 12 -16, 20, 22, 23, 25, 26, 28, 29, and 33 – 38.

Applicants believe the pending claims are in condition for allowance and issuance of a formal Notice of Allowance at an early date is respectfully requested. If a telephone conference

U.S.S.N. 10/565,954
Page No. 8

would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (650) 846-7620.

Respectfully submitted,


Lynn Marcus-Wyner, PhD
Registration No. 34,869

Date: November 6, 2006

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-7620
Fax: 650-845-6504